Neonatal Drug Therapy Manual

Aldactazide

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Hydrochlorothiazide and Spironolactone
Classification: 
Thiazide and Potassium Sparing diuretic
Original Date: 
June 1996
Revised Date: 
March 2022
Indications: 
  • Edema, hypertension
  • May improve lung function in BPD patients.
Administration: 
  • PO
Dosage: 
  • 2 - 4 mg/kg/day divided in 2 doses
Side Effects: 
  • Endocrine and metabolic: electrolyte abnormalities, hyperglycemia
  • Renal: hyperuricemia
Parameters to Monitor: 
  • Serum electrolytes
  • Blood glucose
  • Signs of edema
  • BP
  • Urine output
Compatibility: 

 N/A

References: 

Young TE, Mangum B. Neofax(R). 13th-16th Editions. Raleigh: Acorn Publishing; 2000-2003.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.